Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Knight Therapeutics Inc T.GUD

Alternate Symbol(s):  KHTRF

Knight Therapeutics Inc. is a specialty pharmaceutical company. The Company’s principal business activity is developing, acquiring, in-licensing, out-licensing, manufacturing, marketing and distributing pharmaceutical products in Canada, Latin America and select international markets. It finances other life sciences companies and secures product distribution rights for Canada and select international markets. The Company invests in life sciences venture capital funds whereby the Company may receive preferential access to healthcare products for Canada and select international markets. It develops pharmaceutical products, including those to treat neglected tropical and rare pediatric diseases. The portfolio consists of pharmaceutical products with molecules and includes both in-licensed products such as Lenvima, Cresemba, Halaven, Trelstar, Akynzeo, Ambisome, Minjuvi, Imvexxy as well as products owned by Knight such as Exelon and Impavido.


TSX:GUD - Post by User

Comment by gudisgoodon Aug 08, 2022 12:33pm
131 Views
Post# 34879067

RE:RE:RE:RE:Expectations

RE:RE:RE:RE:Expectations
longrun86 wrote:

I am focussed mostly on the operating performance this Quarter.

My wish list would be revenue north of $68 million and operating EBITDA greater than $15 million.

Adding to my wish list, I would like an update on the guidance as well as some insight into capital allocation timing.

Hope you are all enjoying the summer and getting in sone quality family time!
 

LR




Your EBITDA wish of $15M (22% margin on $68M of revenue) may be overly optimistic since we’ll now have increased spending on marketing, Exelon costs, etc. Unless they absolutely knock the sales out of the park, of course, in which case a lower EBITDA margin would do the job.
 
Here’s Samira (Q1/22 earnings call):
 

No, so as kind of Jeff mentioned also earlier, we had in Q1, kind of because of our -- because teams were locked down for, let's say, at least half of the quarter, we really didn't have commercial or medical spend in Q1 to the level that we would normally have. As we go into Q2 and Q3, where things like conferences and meetings are all happening, we expect that -- so EBITDA margin in Q1 is disproportionately higher than where we expected for the year. What we do expect is kind of in the mid-teens, which is where we ended up for the year last year.

 
Last year’s EBITDA margin was 15.6%.
 
As far as revenue, to hit the $260 million, we need at least $65 million per quarter on average, so $68 million is certainly doable... besides, it’s in the $270 million a year range.

I do share your wish for an upwards revised revenue guidance.

Hope you're enjoying the summer as well! :)
<< Previous
Bullboard Posts
Next >>